These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

80 related articles for article (PubMed ID: 10395030)

  • 1. Reversal by [D-Ala2,D-Leu5]enkephalin of the dopamine transporter loss caused by methamphetamine.
    Tsao LI; Cadet JL; Su TP
    Eur J Pharmacol; 1999 May; 372(3):R5-7. PubMed ID: 10395030
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Delta opioid peptide [D-Ala2, D-Leu5]enkephalin causes a near complete blockade of the neuronal damage caused by a single high dose of methamphetamine: examining the role of p53.
    Hayashi T; Hirata H; Asanuma M; Ladenheim B; Tsao LI; Cadet JL; Su TP
    Synapse; 2001 Mar; 39(4):305-12. PubMed ID: 11169780
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Delta opioid peptide [D-Ala2,D-leu5]enkephalin blocks the long-term loss of dopamine transporters induced by multiple administrations of methamphetamine: involvement of opioid receptors and reactive oxygen species.
    Tsao LI; Ladenheim B; Andrews AM; Chiueh CC; Cadet JL; Su TP
    J Pharmacol Exp Ther; 1998 Oct; 287(1):322-31. PubMed ID: 9765353
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Opioid peptides alleviated while naloxone potentiated methamphetamine-induced striatal dopamine depletion in mice.
    Yu L; Kuo YM; Cherng CF
    J Neural Transm (Vienna); 2001; 108(11):1231-7. PubMed ID: 12030189
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nature of methamphetamine-induced rapid and reversible changes in dopamine transporters.
    Kokoshka JM; Vaughan RA; Hanson GR; Fleckenstein AE
    Eur J Pharmacol; 1998 Nov; 361(2-3):269-75. PubMed ID: 9865517
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Blockade of dopamine transporter and tyrosine hydroxylase activity loss by [D-Ala(2), D-Leu(5)]enkephalin in methamphetamine-treated CD-1 mice.
    Tsao LI; Hayashi T; Su TP
    Eur J Pharmacol; 2000 Sep; 404(1-2):89-93. PubMed ID: 10980266
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [D-Ala2, D-Leu5]enkephalin blocks the methamphetamine-induced c-fos mRNA increase in mouse striatum.
    Hayashi T; Tsao LI; Cadet JL; Su TP
    Eur J Pharmacol; 1999 Feb; 366(2-3):R7-8. PubMed ID: 10082218
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A rapid and reversible change in dopamine transporters induced by methamphetamine.
    Fleckenstein AE; Metzger RR; Gibb JW; Hanson GR
    Eur J Pharmacol; 1997 Apr; 323(2-3):R9-10. PubMed ID: 9128855
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Methamphetamine decreases mouse striatal dopamine transporter activity: roles of hyperthermia and dopamine.
    Sandoval V; Hanson GR; Fleckenstein AE
    Eur J Pharmacol; 2000 Dec; 409(3):265-71. PubMed ID: 11108820
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chronic [D-Ala2, D-Leu5]enkephalin treatment increases the nerve growth factor in adult mouse brain.
    Hayashi T; Su TP
    Eur J Pharmacol; 2003 Mar; 464(2-3):237-9. PubMed ID: 12620518
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Methamphetamine-induced decrease in tryptophan hydroxylase activity: role of 5-hydroxytryptaminergic transporters.
    Fleckenstein AE; Beyeler ML; Jackson JC; Wilkins DG; Gibb JW; Hanson GR
    Eur J Pharmacol; 1997 Apr; 324(2-3):179-86. PubMed ID: 9145769
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hibernation-induction peptide and cell death: [D-Ala2,D-Leu5]enkephalin blocks Bax-related apoptotic processes.
    Tsao LI; Su TP
    Eur J Pharmacol; 2001 Sep; 428(1):149-51. PubMed ID: 11779032
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term methamphetamine-induced decreases of [(11)C]WIN 35,428 binding in striatum are reduced by GDNF: PET studies in the vervet monkey.
    Melega WP; Lacan G; Desalles AA; Phelps ME
    Synapse; 2000 Mar; 35(4):243-9. PubMed ID: 10657033
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Striatal dopamine nerve terminal markers in human, chronic methamphetamine users.
    Wilson JM; Kalasinsky KS; Levey AI; Bergeron C; Reiber G; Anthony RM; Schmunk GA; Shannak K; Haycock JW; Kish SJ
    Nat Med; 1996 Jun; 2(6):699-703. PubMed ID: 8640565
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ontogeny of neurokinin-1 receptor mediation of methamphetamine neurotoxicity in the striatum of the mouse brain.
    Yu J; Allison S; Ibrahim D; Cadet JL; Angulo JA
    Ann N Y Acad Sci; 2002 Jun; 965():247-53. PubMed ID: 12105100
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dose-response and duration effects of acute administrations of cocaine and GBR12909 on dopamine synthesis and transporter in the conscious monkey brain: PET studies combined with microdialysis.
    Tsukada H; Harada N; Nishiyama S; Ohba H; Kakiuchi T
    Brain Res; 2000 Mar; 860(1-2):141-8. PubMed ID: 10727633
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Methamphetamine-induced rapid and reversible reduction in the activities of tryptophan hydroxylase and dopamine transporters: oxidative consequences?
    Hanson GR; Gibb JW; Metzger RR; Kokoshka JM; Fleckenstein AE
    Ann N Y Acad Sci; 1998 May; 844():103-7. PubMed ID: 9668668
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of dopaminergic drugs on the in vivo binding of [3H]WIN 35,428 to central dopamine transporters.
    Scheffel U; Steinert C; Kim SE; Ehlers MD; Boja JW; Kuhar MJ
    Synapse; 1996 Jun; 23(2):61-9. PubMed ID: 8723710
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reduced striatal vesicular monoamine transporters after neurotoxic but not after behaviorally-sensitizing doses of methamphetamine.
    Frey K; Kilbourn M; Robinson T
    Eur J Pharmacol; 1997 Sep; 334(2-3):273-9. PubMed ID: 9369358
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association of dopamine transporter reduction with psychomotor impairment in methamphetamine abusers.
    Volkow ND; Chang L; Wang GJ; Fowler JS; Leonido-Yee M; Franceschi D; Sedler MJ; Gatley SJ; Hitzemann R; Ding YS; Logan J; Wong C; Miller EN
    Am J Psychiatry; 2001 Mar; 158(3):377-82. PubMed ID: 11229977
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.